Loading clinical trials...
Loading clinical trials...
This is an Open Label, Phase IV, Post Authorisation Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily Subcutaneous Metreleptin Treatment in people with Partial Lipodystrophy
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Amryt Pharma
NCT06679270 · Familial Partial Lipodystrophy
NCT02404896 · Familial Partial Lipodystrophy
NCT02527343 · Familial Partial Lipodystrophy
NCT03514420 · Familial Partial Lipodystrophy
NCT02654977 · Familial Partial Lipodystrophy, Nonalcoholic Steatohepatitis, and more
Centre Hospitalier Régional Universitaire de Lille (CHRU) - Hôpital Claude Huriez
Lille
Hopital Pitie-Salpetriere
Paris
Hôpital Saint-Antoine
Paris
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions